Immune‐independent acquired resistance to <scp>PD‐L1</scp> antibody initiated by <scp>PD‐L1</scp> upregulation via <scp>PI3K</scp>/<scp>AKT</scp> signaling can be reversed by anlotinib

Yuan Gao(Tianjin Medical University Cancer Institute and Hospital), Kai Li(Guangdong Academy of Medical Sciences)
Cancer Medicine
June 23, 2023
10.1002/cam4.6195
Cited by 13

Related Papers

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells
|Cell Death and Disease|2020|185
&lt;p&gt;Overexpression of RNF126 Promotes the Development of Colorectal Cancer via Enhancing p53 Ubiquitination and Degradation&lt;/p&gt;
|OncoTargets and Therapy|2020|16
Genomic alteration profile and <scp>PD‐L1</scp> expression among different breast cancer subtypes in Chinese population and their correlations
|Cancer Medicine|2022|4
Changes in PD-L1 expression on microvessel endothelial cells during melanoma tumor growth and the regulation by anlotinib
|Research Square|2023|0